Partners Group to sell stake in PCI Pharma Services for €83 million

Published 15/07/2025, 07:40
Partners Group to sell stake in PCI Pharma Services for €83 million

LONDON - Partners Group Private Equity Limited (LSE:PEYS/PEY) announced Tuesday it has agreed to exit its longstanding investment in PCI Pharma Services while reinvesting a portion to maintain a minority position in the company.

The transaction values PGPE’s stake in PCI at approximately €83 million, aligning with the company’s latest published carrying value as of May 31. PGPE will reinvest about €18 million to retain participation in the pharmaceutical contract development and manufacturing organization’s future growth.

A consortium led by Bain Capital and Kohlberg & Company will acquire a majority stake in PCI Pharma Services as part of the deal, which is expected to close in the second half of 2025, subject to regulatory approvals.

Partners Group initially invested in PCI in 2016, helping transform it from a regional commercial packaging organization into a global contract development and manufacturing organization. In 2020, Kohlberg & Company and Mubadala Investment Company acquired a majority stake while Partners Group maintained a minority position.

"During this phase of ownership, PCI expanded into advanced drug delivery services, development and manufacturing of biologics, and sterile fill-finish services," according to the company statement.

PCI Pharma Services, founded in 2012 and headquartered in Philadelphia, Pennsylvania, currently represents the second largest investee company in PGPE’s portfolio.

PGPE, formerly known as Princess Private Equity Holding Limited, is an investment holding company domiciled in Guernsey that invests in private equity direct investments and is managed by Partners Group.

The information was disclosed in a press release issued by the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.